13th Sep 2005 13:29
Pfizer Statement on Lasofoxifene NEW YORK, Sept. 13 -- Pfizer Inc said today it has received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis. Pfizer said that it will be reviewing its submission with the FDA and considering various possible courses of action. SOURCE Pfizer Inc 09/13/2005 /CONTACT: Mariann Caprino of Pfizer Inc, +1-212-733-4554/ /Company News On-Call: http://www.prnewswire.com/comp/688250.html / /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html / /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Web site: http://www.pfizer.com / (PFE) ENDPFIZER INCRelated Shares:
PFZ.L